Proposed biosimilar pegfilgrastim LA-EP2006 shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects

被引：0
|
作者：
Nakov, Roumen
Gattu, Sreekanth
Wang, Jessie
Velinova, Maria
Skerjanec, Andrej
机构：
[1] Hexal AG, Holzkirchen, Germany
[2] Sandoz Inc, Princeton, NJ USA
[3] PRA Hlth Sci, Groningen, Netherlands
[4] Sandoz AG, Basel, Switzerland
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-14-10
引用
下载
收藏
页数：1
相关论文
共 46 条
  • [41] A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis
    Burmester, Gerd
    Chien, David
    Chow, Vincent
    Gessner, Melissa
    Pan, Jean
    Cohen, Stanley
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (08): : 1003 - 1014
  • [42] BI 695501, a Proposed Biosimilar for Adalimumab, Shows Bioequivalence to Adalimumab Reference Products in a Randomized, Double-Blind Phase I Trial in Healthy Subjects
    Wynne, Christopher
    Petkova, Magdalena
    Rombout, Ferdinand
    Czeloth, Niklas
    Altendorfer, Mario
    Lang, Benjamin
    Frapaise, Francois-Xavier
    Ellis-Pegler, Rod
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [43] Assessment of Comparative Immunogenicity in Biosimilar Development: Immunogenicity and Pharmacokinetics Following a Single Dose of M923, a Proposed Biosimilar for Reference Adalimumab (HUMIRA®), Compared with US- and EU-Sourced Reference Adalimumab in Healthy Subjects
    Hillson, Jan
    Mant, Tim
    Ganguly, Tanmoy
    Avery, William
    Rosano, Molly
    Huntenburg, Carolyn
    Palmer, Donna
    Darne, Siddesh
    Pavlova, Borislava
    Doralt, Jennifer
    Reeve, Russell
    Goel, Niti
    Weilert, Doris
    Rhyne, Paul
    Caminis, John
    Roach, James
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [44] A single-dose, randomized, open-label, four-period, crossover equivalence trial comparing the clinical similarity of the proposed biosimilar rupatadine fumarate to reference Wystamm® in healthy Chinese subjects
    Lin, Sisi
    Lou, Yutao
    Hao, Rui
    Shao, Yiming
    Yu, Jin
    Fang, Lu
    Bao, Meihua
    Yi, Wu
    Zhang, Yiwen
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [45] HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects
    Yang, Jingjing
    Lin, Lili
    Long, Qihe
    Zhang, Qian
    Sun, Guilan
    Zhou, Liang
    Wang, Qingyu
    Zhu, Jun
    Li, Fanfan
    Hu, Wei
    BIODRUGS, 2022, 36 (03) : 393 - 409
  • [46] HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects
    Jingjing Yang
    Lili Lin
    Qihe Long
    Qian Zhang
    Guilan Sun
    Liang Zhou
    Qingyu Wang
    Jun Zhu
    Fanfan Li
    Wei Hu
    BioDrugs, 2022, 36 : 393 - 409
12345